BTIG Reiterates Neutral Rating on Insight Molecular Diagnostics Inc. (IMDX) May 15, 2026 06:25AM
BTIG Reiterates Neutral Rating on Insight Molecular Diagnostics Inc. (IMDX) Apr 1, 2026 06:07AM
Needham Reiterates Buy Rating on Insight Molecular Diagnostics Inc. (IMDX) Mar 27, 2026 05:58AM
IMDX submits GraftAssureDx to FDA for transplant rejection testing Mar 26, 2026 04:06PM
IMDX study shows GraftAssure assay outperforms standard rejection tests Mar 13, 2026 08:00AM


Feb 26, 2026 04:41PM Insight Molecular Diagnostics partners with Quest Diagnostics for specimen collection services
Jan 13, 2026 09:05AM IMDX supports call for decentralized transplant monitoring test kits
Jan 5, 2026 12:27PM Needham: 'we believe that IMDX is making good progress towards its GraftAssureDx submissions'
Nov 11, 2025 04:51AM Insight Molecular Diagnostics Inc. (IMDX) PT Raised to $9 at Needham
Oct 13, 2025 04:05PM iMDx hires Steven Tahmooressi as marketing VP ahead of 2026 launch
Oct 6, 2025 07:15AM iMDx reports kidney transplant patient maintained graft without immunosuppression
Sep 8, 2025 07:16AM Insight Molecular Diagnostics launches 5,000-patient registry study
Aug 12, 2025 06:41AM Needham Reiterates Buy Rating on Insight Molecular Diagnostics Inc. (IMDX)
Jun 23, 2025 04:06PM iMDx (IMDX) Reports Strong Head-to-Head Data in Kidney Transplant Rejection Testing